Publications by authors named "Robert Dow"

Claim this Profile
S
Single-Position Synchronal Management of Metastatic Prostate Cancer of the Spine and Femur Using Prone Nailing: A Case Report.
Robert Dow, Scott Gronowicz, Matthew Aceto, Alan Daniels, Bassel Diebo

JBJS Case Connect· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
Ariamala Gopalsamy, Ann E Aulabaugh, Amey Barakat, Kevin C Beaumont, Shawn Cabral, Robert L Dow

J Med Chem· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Kim Huard, Aaron C Smith, Gregg Cappon, Robert L Dow, David J Edmonds, Matthew S Dowling

J Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the Letter to the Editor on "Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol".
Dexter K Bateman, Robert W Dow, Andrzej Brzezinski, Howard Y Bar-Eli, Stephen T Kayiaros

J Arthroplasty· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interventional Removal of Traumatic Nail from Skull Base After Endovascular Coiling of Internal Carotid Artery and Jugular Vein.
Robert Dow, Kumar Shah, Gaurav Gupta, Michael Censullo, Sudipta Roychowdhury

World Neurosurg· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.
Robert L Dow, Mark Ammirati, Scott W Bagley, Samit K Bhattacharya, Leonard Buckbinder

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol.
Dexter K Bateman, Robert W Dow, Andrzej Brzezinski, Howard Y Bar-Eli, Stephen T Kayiaros

J Arthroplasty· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1.
Adam G Schwaid, Chunyan Su, Paula Loos, Jiang Wu, Chuong Nguyen, Robert L Dow

ACS Chem Biol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.
Mark Ammirati, Scott W Bagley, Samit K Bhattacharya, Leonard Buckbinder, Anthony A Carlo, Robert L Dow, Matthew S Dowling

ACS Med Chem Lett· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High specificity in response of the sodium-dependent multivitamin transporter to derivatives of pantothenic acid.
Srinivas Reddy Chirapu, Charles J Rotter, Emily L Miller, Manthena V Varma, Robert L Dow

Curr Top Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medicinal chemistry design principles for liver targeting through OATP transporters.
Meihua Tu, Alan M Mathiowetz, Jeffrey A Pfefferkorn, Kimberly O Cameron, Robert L Dow

Curr Top Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Undesired versus designed enzymatic cleavage of linkers for liver targeting.
Srinivas R Chirapu, Jonathan N Bauman, Heather Eng, Theunis C Goosen, Timothy J Strelevitz, Robert L Dow

Bioorg Med Chem Lett· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.
Robert L Dow, Melissa P Andrews, Jian-Cheng Li, E Michael Gibbs, Angel Guzman-Perez

Bioorg Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.
David A Griffith, Robert L Dow, Kim Huard, David J Edmonds, Scott W Bagley

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.
Kevin J Filipski, Angel Guzman-Perez, Jianwei Bian, Christian Perreault, Gary E Aspnes, Robert L Dow

Bioorg Med Chem Lett· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of spiropiperidine lactam acetyl-CoA carboxylase inhibitors.
Kim Huard, Scott W Bagley, Elnaz Menhaji-Klotz, Cathy Préville, James A Southers, Robert L Dow

J Org Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.
Robert L Dow, Philip A Carpino, Denise Gautreau, John R Hadcock, Philip A Iredale

ACS Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core.
Robert L Dow, Melissa Andrews, Gary E Aspnes, Gayatri Balan, E Michael Gibbs

Bioorg Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Robert L Dow, Jian-Cheng Li, Michael P Pence, E Michael Gibbs, Jennifer L LaPerle

ACS Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.
John R Hadcock, Philip A Carpino, Philip A Iredale, Robert L Dow, Denise Gautreau

BMC Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
John R Hadcock, David A Griffith, Phillip A Iredale, Phillip A Carpino, Robert L Dow

Biochem Biophys Res Commun· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thyroid receptor agonists for the treatment of androgenetic alopecia.
Jie Jack Li, Lorna H Mitchell, Robert L Dow

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.
Robert L Dow, John R Hadcock, Dennis O Scott, Steven R Schneider, Ernest S Paight

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.
Robert L Dow, Philip A Carpino, John R Hadcock, Shawn C Black, Philip A Iredale

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.
David A Griffith, John R Hadcock, Shawn C Black, Philip A Iredale, Philip A Carpino, Robert L Dow

J Med Chem· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis